



# **Humanitarian Device Exemption**

## **Review of Humanitarian Use Devices**

**Nicole Wolanski, CAPT, USPHS**  
**Premarket Approval Program**  
**Office of Device Evaluation**  
**Center for Devices and Radiological Health (CDRH), FDA**

**March 20, 2014**

# Overview

- Premarket Submissions
- HUDs
- HDEs
  - Criteria & Content
  - Approval
  - Key Points
  - Stats

# Devices – Premarket Submissions

- Submissions for marketing clearance/approval
  - 510(k) – substantial equivalence
  - De Novo – classification of low risk devices without predicates
  - PMA – reasonable assurance of safety and effectiveness
  - HDE – reasonable assurance of safety and probable benefit

# HUDs

- Humanitarian Use Device (HUD)
  - For medical devices intended to treat or diagnose a disease or condition affecting fewer than 4,000 individuals in the US per year (21 CFR 814.(n))
  - HUD designation requests are reviewed by Office of Orphan Product Development
  - Additional information - [www.fda.gov/orphan](http://www.fda.gov/orphan)

# HUDs

- Nearly 7,000 rare diseases are known to affect roughly 30 million Americans.
  - approx 80% percent of rare diseases are genetic
  - about 1/2 of all rare diseases affect children
- Pediatric patients – less than 22 years of age



# HDEs – Criteria & Content

- Criteria
  - Received HUD designation from OOPD and
  - Device is not otherwise available
- Content
  - Device description
  - Non clinical data: engineering, software, biocompatibility, etc.
  - Clinical experience
  - Manufacturing
  - Physician and patient labeling

## HDEs - Approval

- Approval Threshold
  - Does not pose unreasonable risk of illness or injury (i.e., **safety** is demonstrated), **AND**
  - **Probable benefit** outweighs the risk (i.e., exempt from effectiveness requirements of a PMA)
- Marketing Approval
  - IRB approval required before the HUD is used (except in emergency situations)
  - Labeling must clearly identify device as a HUD, and that effectiveness for that indication has not been demonstrated

# Key Points

- Requirement to show safety and ***probable benefit***
- HDE approval is marketing approval
- IRB approval required before device is used
- Annual reporting includes reassessment of qualification for HUD
- Draft guidance:
  - [http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm389154.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm389154.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)



## HDE Stats

- 58 approved HDEs
- 8 devices approved under HDEs currently authorized to make a profit
- List of approved HDEs and their Summaries of Safety and Probable Benefit (SSPB) available at:  
<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/HDEApprovals/ucm161827.htm>

# Contact Information

## HUD Designation Information:

Office of Orphan Product Development

Eric Chen - (301) 796-6327

[eric.chen@fda.hhs.gov](mailto:eric.chen@fda.hhs.gov)

## HDE Information:

Nicole Wolanski – 301-796-6570

[nicole.wolanski@fda.hhs.gov](mailto:nicole.wolanski@fda.hhs.gov)

PMA staff – 301-796 -5640

OIR – Runa Musib – 301-796-7014